Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–117 of 117 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Diclofenac Sodium Clear all

Conditions: Elbow Pain, Chronic Pain
Interventions: Diclofenac, Tramadol, Acetaminophen; Drug · Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Coral Springs, Florida • Avon, Ohio

Conditions: Osteoarthritis
Interventions: Diclofenac Topical Sodium Gel 1%; Drug
Lead sponsor: Novartis; Industry
Eligibility: 35 Years and older
Enrollment: 480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Parsippany, New Jersey

Conditions: Acute Pseudophakic Cystoid Macular Edema
Interventions: Bromfenac, Ketorolac, Diclofenac; Drug
Lead sponsor: Bp Consulting, Inc; Network
Eligibility: 18 Years and older
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pain, Ankle Sprain
Interventions: PENNSAID, Diclofenac hydroxyethylpyrrolidine; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Chronic Pain, Osteoarthritis, Hip, Osteoarthritis, Knee
Interventions: NSAID, Tanezumab 2.5 mg, Tanezumab 5 mg; Drug · Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 3,021 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 299
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 187 more

Conditions: Diabetes
Interventions: DHEP; Behavioral
Lead sponsor: Robert Wood Johnson Foundation; Other
Eligibility: 40 Years to 85 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Cervicogenic Headache
Interventions: Diclofenac 1% Topical, Petroleum Jelly; Drug · Other
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Healthy
Interventions: Intravenous diclofenac sodium (DIC075V) 18.75 mg, Intravenous diclofenac sodium (DIC075V) 37.5 mg, Oral diclofenac potassium 50 mg; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer
Interventions: Diclofenac epolamine patch; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pain
Interventions: Zipsor®; Drug
Lead sponsor: Depomed; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Sheffield, Alabama • Stanford, California

Conditions: Low Back Pain
Interventions: Ibuprofen 400 mg, Topical diclofenac; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 69 Years
Enrollment: 198 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Actinic Keratosis
Interventions: Diclofenac sodium, Placebo; Drug · Other
Lead sponsor: Actavis Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 476 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 31
States / cities: Fremont, California • Long Beach, California • Newport Beach, California + 27 more

Conditions: Dental Pain
Interventions: Diclofenac Test (lower dose), Diclofenac Test (upper dose), Celecoxib 400 mg, Placebo; Drug
Lead sponsor: Iroko Pharmaceuticals, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Rotator Cuff Tendonitis, Bicipital Tendonitis, Subdeltoid Bursitis of the Shoulder, Subacromial Bursitis of the Shoulder, Medial Epicondylitis of the Elbow, Lateral Epicondylitis of the Elbow, DeQuervain's Tenosynovitis of the Wrist
Interventions: diclofenac sodium, Matching Placebo; Drug
Lead sponsor: Cerimon Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Soft Tissue Injuries
Interventions: Licart™ (diclofenac epolamine) topical system; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 6 Years to 45 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Little Rock, Arkansas • La Palma, California • DeLand, Florida + 8 more

Conditions: Osteoarthritis Pain of the Knee
Interventions: Diclofenac sodium active topical patch, Placebo patch; Drug
Lead sponsor: Noven Pharmaceuticals, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 10
States / cities: Little Rock, Arkansas • Clearwater, Florida • Doral, Florida + 7 more

Conditions: Osteoarthritis of the Knee
Interventions: PENNSAID Gel, Vehicle; Drug
Lead sponsor: Mallinckrodt; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 260 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 26
States / cities: Tucson, Arizona • Sacramento, California • Clearwater, Florida + 22 more

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip
Interventions: Fasinumab, Diclofenac, Celecoxib, Matching placebo; Drug · Other
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 1,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 71
States / cities: Anniston, Alabama • Mobile, Alabama • Chandler, Arizona + 63 more

Conditions: Renal Insufficiency, Chronic, Hepatic Insufficiency, Healthy
Interventions: Sporanox, Diclofenac Sodium; Drug
Lead sponsor: Javelin Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 3
States / cities: Orlando, Florida • Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Ventricular Repolarization
Interventions: DIC075V; Drug
Lead sponsor: Hospira, now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Osteoarthritis
Interventions: TDS-943 (topical diclofenac sodium 4% spray), celecoxib, placebo; Drug · Other
Lead sponsor: Mika Pharma GmbH; Industry
Eligibility: 40 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 49
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 42 more

Search by objective public record fields.

NonNarcotic Pain Control in Percutaneous Needle Tenotomy of Elbow

Efficacy and Safety of Diclofenac Sodium Gel in Knee Osteoarthritis

Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%

Efficacy of PENNSAID® for Pain Management in the Emergency Department

Long Term Safety and Efficacy Study of Tanezumab in Subjects With Osteoarthritis of the Hip or Knee

Diabetes Health Enhancement Program to Improve Health of People With Diabetes

Diclofenac Gel in the Treatment of Cervicogenic Headache

Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium

Test Uniformity of Transdermal Drug Delivery to Breast Using Diclofenac Epolamine

Safety and Tolerability of Zipsor® in Pediatric Subjects (Ages 12-17 Years) With Mild to Moderate Acute

Acute Low Back Pain. Topical Diclofenac and Oral Ibuprofen.

A Study Comparing Diclofenac Sodium Gel 3% to Solaraze® (Diclofenac Sodium) Gel 3% in the Treatment of Actinic Keratosis

Study of Diclofenac Capsules to Treat Dental Pain

Diclofenac Patch for Treatment of Mild to Moderate Tendonitis or Bursitis

Study of PK and Safety of the LicartTM Topical System in Pediatric and Adult Participants With Minor Soft Tissue Injury

A 12-week Study to Evaluate the Efficacy and Safety of HP-5000 in Subjects With Osteoarthritis Pain of the Knee

Exploratory Study of PENNSAID Gel to Treat Symptoms of Knee Osteoarthritis

Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip

Open-Label, Single-Dose Study to Evaluate the Safety and PK of DIC075V in Subjects With Renal Insufficiency and Hepatic Impairment Compared to Healthy Subjects and Evaluate the Safety and Pharmacokinetics of HPβCD When Administered in DIC075V Compared to Sporanox® in Healthy Subjects

A Randomized, Single-Dose, Comparative, Positive and Placebo Controlled, Four-Way, Four Period, Cross-Over Study to Evaluate the Effect of DIC075V on QTc Intervals in Healthy Subjects

Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II